NO313178B1 - Sammensetning til fremskaffelse av en immunrespons mot et antigen hos et dyr, sett til anvendelse derav, samt anvendelse aven först opplöselig form av et antigen og en andre uopplöseligform av antigenet ved fremstilling av sammensetningen elle - Google Patents
Sammensetning til fremskaffelse av en immunrespons mot et antigen hos et dyr, sett til anvendelse derav, samt anvendelse aven först opplöselig form av et antigen og en andre uopplöseligform av antigenet ved fremstilling av sammensetningen elle Download PDFInfo
- Publication number
- NO313178B1 NO313178B1 NO19933261A NO933261A NO313178B1 NO 313178 B1 NO313178 B1 NO 313178B1 NO 19933261 A NO19933261 A NO 19933261A NO 933261 A NO933261 A NO 933261A NO 313178 B1 NO313178 B1 NO 313178B1
- Authority
- NO
- Norway
- Prior art keywords
- antigen
- cells
- physiochemical
- animal
- immune response
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title claims abstract description 111
- 108091007433 antigens Proteins 0.000 title claims abstract description 111
- 102000036639 antigens Human genes 0.000 title claims abstract description 111
- 230000028993 immune response Effects 0.000 title claims abstract description 33
- 241001465754 Metazoa Species 0.000 title claims description 28
- 239000000203 mixture Substances 0.000 title claims description 18
- 238000002360 preparation method Methods 0.000 title claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims abstract description 25
- 210000002443 helper t lymphocyte Anatomy 0.000 claims abstract description 17
- 241000712461 unidentified influenza virus Species 0.000 claims abstract description 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 22
- 241000700605 Viruses Species 0.000 claims description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 7
- 230000002209 hydrophobic effect Effects 0.000 claims description 5
- 101710154606 Hemagglutinin Proteins 0.000 claims description 4
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 4
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 4
- 101710176177 Protein A56 Proteins 0.000 claims description 4
- 239000000185 hemagglutinin Substances 0.000 claims description 4
- 229960005486 vaccine Drugs 0.000 claims description 4
- 108700006640 OspA Proteins 0.000 claims description 3
- 241000589969 Borreliella burgdorferi Species 0.000 claims description 2
- 238000012986 modification Methods 0.000 claims description 2
- 230000004048 modification Effects 0.000 claims description 2
- 229940099789 ospa protein Drugs 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims 1
- 230000002163 immunogen Effects 0.000 abstract description 12
- 230000003612 virological effect Effects 0.000 abstract description 6
- 210000004027 cell Anatomy 0.000 abstract description 4
- 230000004044 response Effects 0.000 description 11
- 101710105714 Outer surface protein A Proteins 0.000 description 9
- 241000700198 Cavia Species 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 230000005875 antibody response Effects 0.000 description 5
- 230000030741 antigen processing and presentation Effects 0.000 description 5
- 238000011260 co-administration Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 241000282412 Homo Species 0.000 description 4
- 206010022000 influenza Diseases 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 101800000385 Transmembrane protein Proteins 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- 230000016173 B cell antigen processing and presentation Effects 0.000 description 1
- 102000019260 B-Cell Antigen Receptors Human genes 0.000 description 1
- 108010012919 B-Cell Antigen Receptors Proteins 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 241000589970 Spirochaetales Species 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 231100000481 chemical toxicant Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229960003983 diphtheria toxoid Drugs 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 125000003473 lipid group Chemical group 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000008884 pinocytosis Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A61K2039/55594—Adjuvants of undefined constitution from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Plant Substances (AREA)
- Jib Cranes (AREA)
- Radar Systems Or Details Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94317392A | 1992-09-14 | 1992-09-14 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO933261D0 NO933261D0 (no) | 1993-09-13 |
| NO933261L NO933261L (no) | 1994-03-15 |
| NO313178B1 true NO313178B1 (no) | 2002-08-26 |
Family
ID=25479200
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19933261A NO313178B1 (no) | 1992-09-14 | 1993-09-13 | Sammensetning til fremskaffelse av en immunrespons mot et antigen hos et dyr, sett til anvendelse derav, samt anvendelse aven först opplöselig form av et antigen og en andre uopplöseligform av antigenet ved fremstilling av sammensetningen elle |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US5662909A (fi) |
| EP (1) | EP0588578B2 (fi) |
| JP (1) | JP2512689B2 (fi) |
| AT (1) | ATE187338T1 (fi) |
| AU (1) | AU677592B2 (fi) |
| CA (1) | CA2105629A1 (fi) |
| DE (1) | DE69327214T3 (fi) |
| DK (1) | DK0588578T4 (fi) |
| ES (1) | ES2141750T5 (fi) |
| FI (1) | FI110234B (fi) |
| GR (1) | GR3032543T3 (fi) |
| IL (2) | IL106968A (fi) |
| NO (1) | NO313178B1 (fi) |
| PT (1) | PT588578E (fi) |
| ZA (1) | ZA936629B (fi) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6967088B1 (en) * | 1995-03-16 | 2005-11-22 | Allergan, Inc. | Soluble recombinant botulinum toxin proteins |
| ZA964896B (en) * | 1995-06-07 | 1997-01-08 | Connaught Lab | Expression of lipoproteins |
| US6251405B1 (en) * | 1995-06-07 | 2001-06-26 | Connaught Laboratories, Inc. | Immunological combination compositions and methods |
| AU2487300A (en) | 1998-12-31 | 2000-07-31 | Chiron Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| WO2000039303A2 (en) * | 1998-12-31 | 2000-07-06 | Chiron Corporation | Modified hiv env polypeptides |
| EP1141313A2 (en) * | 1998-12-31 | 2001-10-10 | Chiron Corporation | Improved expression of hiv polypeptides and production of virus-like particles |
| US7935805B1 (en) * | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
| US20050106137A1 (en) * | 2000-05-05 | 2005-05-19 | Stephen Grimes | Chimeric peptide immunogens |
| ES2406405T3 (es) * | 2000-12-27 | 2013-06-06 | Gilead Sciences, Inc. | Aztreonam inhalable sin arginina para tratamiento y prevención de infecciones bacterianas pulmonares |
| AU2002320314A1 (en) * | 2001-07-05 | 2003-01-21 | Chiron, Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| EP2292772A1 (en) * | 2001-07-05 | 2011-03-09 | Novartis Vaccines and Diagnostics, Inc. | HIV vaccination with a DNA encoding a HIV polypeptide and a HIV polypeptide |
| WO2003020876A2 (en) * | 2001-08-31 | 2003-03-13 | Chiron Corporation | Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof |
| US20030170614A1 (en) * | 2001-08-31 | 2003-09-11 | Megede Jan Zur | Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof |
| US7425331B2 (en) * | 2002-04-10 | 2008-09-16 | Protalex, Inc. | Protein A methods of use |
| US7211258B2 (en) * | 2002-04-10 | 2007-05-01 | Protalex, Inc. | Protein A compositions and methods of use |
| US6814729B2 (en) | 2002-06-27 | 2004-11-09 | Technovision Gmbh | Laser vision correction apparatus and control method |
| EP2550362B1 (en) | 2010-03-25 | 2017-01-04 | Oregon Health&Science University | Cmv glycoproteins and recombinant vectors |
| PT2691530T (pt) | 2011-06-10 | 2018-05-10 | Univ Oregon Health & Science | Glicoproteínas e vectores recombinantes cmv |
| US20130189754A1 (en) | 2011-09-12 | 2013-07-25 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
| US9402894B2 (en) | 2011-10-27 | 2016-08-02 | International Aids Vaccine Initiative | Viral particles derived from an enveloped virus |
| ES2631608T3 (es) | 2012-06-27 | 2017-09-01 | International Aids Vaccine Initiative | Variante de la glicoproteína Env del VIH-1 |
| US20150065381A1 (en) | 2013-09-05 | 2015-03-05 | International Aids Vaccine Initiative | Methods of identifying novel hiv-1 immunogens |
| EP2873423B1 (en) | 2013-10-07 | 2017-05-31 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
| EP3069730A3 (en) | 2015-03-20 | 2017-03-15 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
| EP3072901A1 (en) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4496538A (en) * | 1982-07-06 | 1985-01-29 | Connaught Laboratories, Inc. | Haemophilus influenzae b polysaccharide-diphtheria toxoid conjugate vaccine |
| US4619828A (en) * | 1982-07-06 | 1986-10-28 | Connaught Laboratories, Inc. | Polysaccharide exotoxoid conjugate vaccines |
| GB8610983D0 (en) * | 1986-05-06 | 1986-06-11 | Connaught Lab | Enhancement of antigen immunogenicity |
| US4946676A (en) * | 1986-08-27 | 1990-08-07 | De Staat Der Nederlanden | Vaccine comprising an immunogenic protein and, as an adjuvant, a substantially non-immunogenic, sequentially homologous peptide |
| EP0270295A3 (en) * | 1986-12-03 | 1989-08-02 | Connaught Laboratories Limited | Conjugate vaccine |
| DK425789A (da) * | 1988-08-31 | 1990-03-01 | Smithkline Beecham Corp | Vaccinale polypeptider |
| JPH0678245B2 (ja) * | 1989-07-04 | 1994-10-05 | 東興薬品工業株式会社 | 鼻腔内噴霧投与用インフルエンザワクチンゲル製剤 |
| WO1992000055A1 (en) * | 1990-06-15 | 1992-01-09 | Yale University | Compositions and methods for the prevention and diagnosis of lyme disease |
| JPH06511154A (ja) * | 1991-10-18 | 1994-12-15 | コノート ラボラトリーズ インコーポレイテッド | 組換えＢｏｒｒｅｌｉａタンパクの製造法 |
-
1993
- 1993-09-07 CA CA002105629A patent/CA2105629A1/en not_active Abandoned
- 1993-09-08 ZA ZA936629A patent/ZA936629B/xx unknown
- 1993-09-08 AU AU46226/93A patent/AU677592B2/en not_active Ceased
- 1993-09-10 IL IL10696893A patent/IL106968A/en not_active IP Right Cessation
- 1993-09-13 ES ES93307185T patent/ES2141750T5/es not_active Expired - Lifetime
- 1993-09-13 DK DK93307185T patent/DK0588578T4/da active
- 1993-09-13 PT PT93307185T patent/PT588578E/pt unknown
- 1993-09-13 AT AT93307185T patent/ATE187338T1/de not_active IP Right Cessation
- 1993-09-13 DE DE69327214T patent/DE69327214T3/de not_active Expired - Fee Related
- 1993-09-13 NO NO19933261A patent/NO313178B1/no unknown
- 1993-09-13 EP EP93307185A patent/EP0588578B2/en not_active Expired - Lifetime
- 1993-09-14 JP JP5229041A patent/JP2512689B2/ja not_active Expired - Lifetime
- 1993-09-14 FI FI934013A patent/FI110234B/fi not_active IP Right Cessation
-
1995
- 1995-02-08 US US08/385,587 patent/US5662909A/en not_active Expired - Fee Related
- 1995-06-06 US US08/470,278 patent/US5837264A/en not_active Expired - Lifetime
-
1997
- 1997-02-18 US US08/801,152 patent/US5853736A/en not_active Expired - Fee Related
-
1998
- 1998-11-17 US US09/193,682 patent/US6024963A/en not_active Expired - Lifetime
-
1999
- 1999-05-23 IL IL13007599A patent/IL130075A0/xx unknown
-
2000
- 2000-02-02 GR GR20000400239T patent/GR3032543T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2141750T5 (es) | 2005-12-01 |
| DE69327214T3 (de) | 2005-12-01 |
| EP0588578A1 (en) | 1994-03-23 |
| FI934013A0 (fi) | 1993-09-14 |
| CA2105629A1 (en) | 1994-03-15 |
| JPH06192125A (ja) | 1994-07-12 |
| US5662909A (en) | 1997-09-02 |
| GR3032543T3 (en) | 2000-05-31 |
| EP0588578B2 (en) | 2005-04-13 |
| IL106968A0 (en) | 1993-12-28 |
| NO933261L (no) | 1994-03-15 |
| DK0588578T3 (da) | 2000-03-27 |
| IL106968A (en) | 1999-10-28 |
| EP0588578B1 (en) | 1999-12-08 |
| DE69327214T2 (de) | 2000-09-07 |
| JP2512689B2 (ja) | 1996-07-03 |
| DE69327214D1 (de) | 2000-01-13 |
| ES2141750T3 (es) | 2000-04-01 |
| US6024963A (en) | 2000-02-15 |
| ATE187338T1 (de) | 1999-12-15 |
| AU4622693A (en) | 1994-03-24 |
| IL130075A0 (en) | 2000-02-29 |
| FI110234B (fi) | 2002-12-31 |
| AU677592B2 (en) | 1997-05-01 |
| ZA936629B (en) | 1994-03-30 |
| DK0588578T4 (da) | 2005-07-25 |
| NO933261D0 (no) | 1993-09-13 |
| PT588578E (pt) | 2000-05-31 |
| US5853736A (en) | 1998-12-29 |
| FI934013A (fi) | 1994-03-15 |
| US5837264A (en) | 1998-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO313178B1 (no) | Sammensetning til fremskaffelse av en immunrespons mot et antigen hos et dyr, sett til anvendelse derav, samt anvendelse aven först opplöselig form av et antigen og en andre uopplöseligform av antigenet ved fremstilling av sammensetningen elle | |
| US5194254A (en) | Enhancement of antigen immunogenicity | |
| US4950480A (en) | Enhancement of antigen immunogenicity | |
| Bona et al. | Towards development of T-cell vaccines | |
| US5686078A (en) | Primary and secondary immunization with different physio-chemical forms of antigen | |
| Abdel-Motal et al. | Mechanism for increased immunogenicity of vaccines that form in vivo immune complexes with the natural anti-Gal antibody | |
| EP0658118A1 (en) | Vaccines against group c neisseria meningitidis | |
| Snider et al. | Enhanced antigen immunogenicity induced by bispecific antibodies. | |
| Lett et al. | Immunogenicity of polysaccharides conjugated to peptides containing T-and B-cell epitopes | |
| Smith et al. | Induction of T-cell immunity to oligosaccharide antigens immobilized on crystalline bacterial surface layers (S-layers) | |
| SJÖLANDER et al. | N-Linked Glycans in the CD4-Binding Domain of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein gp160 Are Essential for thein VivoPriming of T Cells Recognizing an Epitope Located in Their Vicinity | |
| EP0596959B1 (en) | Self-adjuvanting peptide vaccine delivery system and production thereof | |
| Sjölander et al. | Induction of homologous virus neutralizing antibodies in guinea-pigs immunized with two human immunodeficiency virus type 1 glycoprotein gp120-ISCOM preparations. A comparison with other adjuvant systems | |
| Robinson et al. | Palmitic acid conjugation of a protein antigen enhances major histocompatibility complex class II-restricted presentation to T cells. | |
| EP0166548A2 (en) | Broad spectrum vaccine against gonorrhea | |
| EP0544712B1 (en) | Neuraminidase and galactose oxidase as vaccine adjuvant | |
| US6355414B1 (en) | Immunopotentiating formulations for vaccinal use | |
| Del Giudice | In vivo carrier effect of heat shock proteins in conjugated vaccine constructs | |
| WO1991012819A1 (en) | Improved immunogenic compositions | |
| Balasa et al. | Immunotargeting of thyroglobulin on antigen presenting cells abrogates natural tolerance in the absence of adjuvant | |
| CA1327523C (en) | Antigen immunogenicity | |
| AU657565B2 (en) | Self-adjuvanting peptide vaccine delivery system and production thereof |